Massachusetts 340B lawsuit: what covered entities should review now
Five Massachusetts hospitals sued Eli Lilly over 340B claims-data requirements. Here’s what covered entities and FQHCs can review while the case proceeds.
Healthcare Advocacy Across the Northeast
Lanton Strategies represents healthcare providers, hospitals, health systems, biotechnology companies, pharmaceutical manufacturers and industry associations before state legislatures and regulatory agencies across the Northeast. Learn how our government affairs services help organizations address legislation, rulemaking and policies affecting their businesses.
340B Rebate Pilot Returns to Court: What Covered Entities and Manufacturers Should Watch
Hospitals are challenging HRSA’s revised 340B rebate pilot before its planned January 1, 2027 launch. Covered entities, pharmacies and manufacturers should understand the legal and operational issues now.
What HRSA’s Revised 340B Rebate Pilot Means for Contract Pharmacies, Health Systems and FQHCs
HRSA’s revised 340B rebate pilot begins January 1, 2027. Here is what covered entities, health systems, FQHCs and contract pharmacies need to know about scope, deadlines, cash flow and compliance.
340B Rebates: Who Bears the Cost of Changing How the Program Works?
HRSA's revised 340B rebate pilot raises new questions about drug purchasing, cash flow, transaction verification and administrative costs. This article examines the concerns of manufacturers and hospitals, the pilot's regulatory safeguards, and the financial, legal and operational considerations facing covered entities, pharmacies and their service providers.